All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Is birtamimab an option for patients with advanced AL amyloidosis at high risk for early death?
Featured:
Morie GertzDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition , the Multiple Myeloma Hub was pleased to speak to Morie Gertz, Mayo Clinic, Rochester, US. We asked, Is birtamimab an option for patients with advanced amyloid light-chain (AL) amyloidosis at high risk for early death?
Is birtamimab an option for patients with advanced AL amyloidosis at high risk for early death?
Gertz opens by discussing the current treatment options available for patients with AL amyloidosis, noting that they are primarily preventative and there is a lack of treatment options for existing amyloid deposits; limiting options for patients who receive a late diagnosis. Gertz goes on to discuss birtamimab as an amyloid depleting antibody that has the potential to be effective at targeting existing amyloid deposits.
Gertz concludes by discussing that the post hoc analysis from a study terminated back in April 2018 has led to the initiation of a phase III trial (AFFIRM-AL, NCT04973137), currently recruiting treatment-naive patients with Stage IV cardiac AL amyloidosis.